6-(4-amino-2,6-dichlorophenoxy)-4-isopropylpyridazin-3(2H)-one(WXG00197)

Resmetirom Intermediate (CAS 920509-28-0)‌
Google Keywords: Resmetirom Intermediate, CAS 920509-28-0, Pharma Intermediates, Anticancer Synthesis, GMP Chemicals

‌Product Overview‌

A high-purity building block for synthesizing ‌Resmetirom‌, a promising drug targeting metabolic disorders and cancers. Ideal for API production with ‌>99.5% purity‌ and scalable processes.
‌Key Use‌: Pharmaceutical R&D, oncology therapeutics, clinical trial materials.

✅ ‌Key Benefits‌

🔹 ‌Ultra-High Purity‌ | ≥99.5% (HPLC/GC)
🔹 ‌GMP Compliance‌ | ICH Q7 standards
🔹 ‌Long Stability‌ | 24-month shelf life

🧪 ‌Applications‌

1. Oncology drug synthesis (e.g., thyroid cancer, NASH)

2. Preclinical/clinical drug development

3. cGMP-compliant contract manufacturing

📜 ‌Quality & Compliance‌

• ‌Testing‌: HPLC, GC, NMR, mass spectrometry

• ‌Standards‌: USP/EP, ISO 9001:2015

📈 ‌Market Outlook‌

Global oncology intermediates market growing at ‌8.2% CAGR‌ (2023-2030), driven by Resmetirom’s potential in MASH and cancer therapies.

Streamline your drug development with Resmetirom Intermediate – precision, compliance, and scalability delivered.